Platelet-rich Fibrin(PRF) Membrane in Ophthalmic Diseases

Summary

The goal of this clinical trial is to observe the role of PRF in treating ophthalmic diseases.The efficacy and safety of PRF were validated for four ophthalmic conditions: macular hole, pterygium, corneal ulcer, and patients undergoing trabeculectomy for glaucoma. The main question aims to answer is PRF's effectiveness in ocular surface and fundus diseases. Participants will be divided into 2 groups, the experimental group will be treated with PRF and the control group will be treated with conventional surgery, with a 12-month postoperative follow-up to determine the role of PRF on wound healing in ophthalmic diseases.

Conditions

• Platelet-rich Fibrin
• Macular Holes
• Pterygium
• Glaucoma

Interventions

PROCEDURE

PRF membrane tamponade surgery in macular hole

A specially formulated PRF membrane, as described previously, was filled into the macular hole to promote fissure repair.

PROCEDURE

ILM peeling in macular hole

The treatment of the macular hole was ILM peeling.

PROCEDURE

PRF membrane grafting in pterygium

Used of autologous PRF membrane to cover the exposed conjunctiva after pterygium excision.

PROCEDURE

Autologous conjunctival transplantation in pterygium

Used of autologous conjunctiva to cover exposed sclera after pterygium excision

PROCEDURE

autologous PRF membrane grafting in trabeculectomy for glaucoma

Used of autologous PRF membranes to cover the exposed sclera after trabeculectomy for glaucoma.

PROCEDURE

Amniotic membrane in trabeculectomy for glaucoma

Used of amniotic to cover the exposed sclera after trabeculectomy for glaucoma.

PROCEDURE

PRF membrane grafting incorneal ulcer

After surgical debridement of corneal ulcers, autologous PRF membrane was placed over the corneal wound to promote corneal healing

PROCEDURE

Amniotic membrane in corneal ulcer

After surgical debridement of corneal ulcers, autologous amniotic membrane was placed over the corneal wound to promote corneal healing

Sponsors & Collaborators

• Lei Du

  lead OTHER

Principal Investigators

• Lei Du · Renmin Hospital of Wuhan University

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

20 Years

Max Age

90 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2023-01-01

Primary Completion

2025-06-30

Completion

2025-12-31

Countries

• China

Study Locations